Skip to main content
. 2023 Nov 30;14:1302227. doi: 10.3389/fphar.2023.1302227

FIGURE 4.

FIGURE 4

MSM ameliorates HFD-induced obesity and hepatic steatosis. (A–K) C57BL/6 male mice fed HFD were treated with PBS, 200 mg/kg/day p.o. MSM, or 400 mg/kg/day p.o. MSM for 4 weeks. LFD-fed mice of the same age were used as a negative control. (A) Body weight of mice treated as indicated. (B) Food intake during the treatment period. Gross liver morphology (C) and total liver mass (D) of mice in each group indicated. (E–G) Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) levels. (H) Hematoxylin and eosin staining and Oil red O staining of liver sections from mice in each group as indicated. Scale bar, 100 µm. (I) Histological non-alcoholic fatty liver disease (NAFLD) activity score (NAS). (J) Quantified Oil red O-stained area. (K) RT-qPCR analysis of hepatic lipogenic gene expression from mice in each group as indicated. Data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 (one-way ANOVA, followed by Tukey’s test).